A cohort study of nevirapine tolerance in clinical practice: French Aquitaine Cohort, 1997-1999.

We performed a retrospective study to evaluate, under routine circumstances, the tolerance and immunovirological changes associated with antiretroviral regimens that contain nevirapine in 137 patients (88% were antiretroviral experienced). During a mean follow-up of 11 months, 33% of patients reported side effects attributed to nevirapine, and 21% discontinued treatment because of poor tolerance. Administration of antihistamines or corticosteroids at the initiation of treatment was not protective against adverse events (relative risk, 0.82; 95% confidence interval, 0.49-1.38). The proportion of patients with hepatitis C virus (HCV) and/or hepatitis B virus (HBV) coinfection who had alanine aminotransferase levels of >100 IU/L increased from 19.4% at baseline to 42.9% at month 12 of follow-up (P=.02). We noticed a significant increase of the proportion of patients with total cholesterol levels of >5.5 mM (P=.02). We have shown that there is a high level of discontinuation of nevirapine therapy in clinical practice and that side effects were not prevented by administration of antihistamines or corticosteroids. Coinfection with HCV or HBV increased the risk of hepatotoxicity, which lead to the cautious use of nevirapine for such patients.

[1]  V. Soriano,et al.  Liver toxicity caused by nevirapine. , 2002, AIDS.

[2]  B Clotet,et al.  Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile , 2001, AIDS.

[3]  J. Miro,et al.  Rapid Communications: Failure of a Short‐Term Prednisone Regimen to Prevent Nevirapine‐Associated Rash: A Double‐Blind Placebo‐Controlled Trial: The GESIDA 09/99 Study , 2001, Journal of acquired immune deficiency syndromes.

[4]  G. Ippolito,et al.  Female sex and the use of anti-allergic agents increase the risk of developing cutaneous rash associated with nevirapine therapy. , 2001, AIDS.

[5]  D. Bangsberg,et al.  Adverse effects of nevirapine , 2001, The Lancet.

[6]  Andrew Phillips,et al.  Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy , 2001, AIDS.

[7]  Geoffrey Scott,et al.  Prophylaxis with a nevirapine-containing triple regimen after exposure to HIV-1 , 2001, The Lancet.

[8]  Stuart Johnson,et al.  Adverse effects associated with use of nevirapine in HIV postexposure prophylaxis for 2 health care workers. , 2000, JAMA.

[9]  V. Soriano,et al.  Prevention of nevirapine-associated exanthema using slow dose escalation and/or corticosteroids , 2000, AIDS.

[10]  H. Ochs,et al.  Progressive specific immune attrition after primary, secondary and tertiary immunizations with bacteriophage ΦX174 in asymptomatic HIV-1 infected patients , 2000, AIDS.

[11]  P. Couzigou,et al.  Severe hepatic cytolysis: incidence and risk factors in patients treated by antiretroviral combinations. Aquitaine Cohort, France, 1996-1998. Groupe dEpidémiologie Clinique de Sida en Aquitaine (GECSA). , 1999, AIDS.

[12]  J. Lang,et al.  Prednisolone does not prevent the occurrence of nevirapine-induced rashes. , 1999, AIDS.

[13]  P. Cadrobbi,et al.  Severe hepatic failure related to nevirapine treatment. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  J. Gatell,et al.  Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine. , 1999, AIDS.

[15]  J. Montaner,et al.  A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study. , 1998, JAMA.

[16]  R. Salamon,et al.  [Human immunodeficiency virus infection and AIDS in Aquitaine. 10 years' experience of a hospital information system, 1985-1995. Le Groupe d'Epidemiologie Clinique du SIDA en Aquitaine (GECSA)]. , 1997, Presse medicale.

[17]  M. Niu,et al.  Nevirapine, Zidovudine, and Didanosine Compared with Zidovudine and Didanosine in Patients with HIV-1 Infection , 1996, Annals of Internal Medicine.

[18]  D. Cooper,et al.  A controlled trial of nevirapine plus zidovudine versus zidovudine alone in p24 antigenaemic HIV‐infected patients , 1996, AIDS.

[19]  D. Francisci,et al.  A randomized, double-blind trial on the use of a triple combination including nevirapine, a nonnucleoside reverse transcriptase HIV inhibitor, in antiretroviral-naive patients with advanced disease. , 1999, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[20]  J. Montaner,et al.  A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study. , 1998, JAMA.